Peptide Library · checked July 28, 2026

Survodutide

Survodutide has published phase 3 placebo-controlled obesity and liver-fat results. That is substantial human evidence, and the original papers still call it investigational. The trials do not create FDA approval, prove superiority to another medicine, or authenticate a different product.

SupportedMore than one relevant human source, or one strong source, supports the narrow conclusion; material limits remain.How labels work →

TL;DR

The lowdown

Four answers first. The source record follows.

01 · Identity

What is it?

Investigational dual glucagon/GLP-1 receptor agonist identified as Survodutide and BI 456906

02 · Human evidence

What do humans show?

Published phase 3 placebo-controlled obesity and MASLD trials

Comparison limitSeparate placebo-controlled trials do not establish which medicine is better

03 · U.S. status

Where does FDA stand?

Investigational in the reviewed original papers; no exact FDA approval action identified

04 · Risks

What is known—and not?

In SYNCHRONIZE-1, gastrointestinal symptoms were the most common adverse events, reported in 80.9% and 89.7% of the Survodutide groups versus 47.9% with placebo; the paper reported no deaths. In the phase 2 MASH trial, nausea, diarrhea, and vomiting were more frequent with Survodutide, and serious adverse events occurred in 8% with Survodutide and 7% with placebo.

U.S. status · July 28, 2026

Approval, compounding, product, sport.

FDA approval: No exact FDA approval action was identified in the reviewed record, and the original papers describe Survodutide as investigational. A negative database search is not permission, a legal conclusion, or product authentication.
U.S. federal record: Current original papers describe Survodutide as investigational; no exact FDA approval action was identified in the reviewed record
Product identity: A shared Survodutide or BI 456906 name does not authenticate another product
Sport: Not specifically named in WADA's 2026 List. Class and approval-status rules still apply, so absence by name is not clearance; athletes should verify the exact product with an anti-doping organization.

This reports the dated federal and sport record. It does not determine whether a particular product or transaction complies with state or federal law, and it is not legal advice.

What it is

Survodutide is the dual glucagon/GLP-1 receptor agonist also called BI 456906. FDA maps it under UNII 2ALA66NS64. Receptor overlap does not make it semaglutide, tirzepatide, retatrutide, or another incretin drug.

That receptor description does not make it interchangeable with another dual, triple, or single receptor agonist. The study results belong to defined subcutaneous investigational products used under controlled protocols.

Why people care

Survodutide sits in the crowded next-generation metabolic-drug conversation because it targets both the glucagon and GLP-1 receptors and now has published phase 3 results. The useful question is not whether the findings are “real”—they are meaningful human evidence—but what they do and do not establish. A positive investigational trial is not an FDA approval, a head-to-head comparison, or a certificate of identity for an unrelated product.

What humans actually show

Phase 3 obesity trial: SYNCHRONIZE-1 randomized 725 adults with obesity, or overweight plus a weight-related complication, without diabetes. Under the treatment-regimen estimand, mean body-weight change through week 76 was −12.2% and −13.0% in the two Survodutide groups versus −5.4% with placebo. At least 5% weight reduction occurred in 72.6%, 71.9%, and 46.3%, respectively. This was a placebo comparison, not a head-to-head drug comparison.
Phase 3 MASLD trial: A 216-person trial in adults with obesity and at-risk metabolic dysfunction-associated steatotic liver disease reported at least 30% MRI-assessed liver-fat reduction in 68.5% with Survodutide and 28.6% with placebo at week 48; mean body-weight change was −8.7% and −1.4%. MRI liver fat is not a biopsy fibrosis endpoint or a long-term clinical outcome.
Phase 2 obesity trial: A dose-finding trial enrolled 387 adults with overweight or obesity without diabetes; 386 received study treatment and 233 completed the 46-week treatment period. Planned-treatment body-weight changes ranged from −6.2% to −14.9% across Survodutide groups versus −2.8% with placebo. High attrition and the absence of an active comparator limit transfer beyond this trial.
Phase 2 MASH and fibrosis trial: Among 293 participants who received study treatment, MASH improvement without worsening fibrosis occurred in 47%, 62%, and 43% of the three Survodutide groups versus 14% with placebo. Fibrosis improvement by at least one stage occurred in 34%, 36%, 34%, and 22%, respectively. The dose-response pattern was not monotonic, follow-up was 48 weeks, and the study does not establish long-term clinical benefit.
Cirrhosis pharmacology study: An open-label nonrandomized study included 82 people across small cohorts with and without cirrhosis. It provides pharmacokinetic, tolerability, and exploratory-marker evidence—not controlled cirrhosis efficacy evidence.

Mechanistic and nonhuman evidence

The candidate-selection program tested 19 dual glucagon/GLP-1 receptor agonists in engineered cells, primary rat hepatocytes, and mouse models. The results support the proposed dual-receptor mechanism and explain why Survodutide advanced. Cell signaling, mouse body weight, and target-engagement biomarkers are not human clinical outcomes and cannot establish comparative benefit.

FDA and U.S. status

The current original phase 3 papers describe Survodutide as investigational or under investigation. An exact-active-ingredient Drugs@FDA API search returned no match in the dated source pass, and FDA's 2026 novel-drug page, current through July 24 at review, did not list it. Those negative searches support a careful record of what was not located; PepCurrent does not turn them into a broader legal conclusion.

An FDA substance identifier establishes chemical identity. It does not establish approval, a reviewed indication, or the identity of a marketed product.

Risks and warning limits

No FDA-approved Survodutide prescribing information was identified. The trial record therefore does not create a complete labeled contraindication, pregnancy, rare-event, long-term, or interaction profile.

What remains unknown

The outcome and exact wording of any future FDA application or decision.
Long-term rare adverse effects and clinical outcomes beyond the reported windows.
Full SYNCHRONIZE-2 diabetes outcomes; its completed registry had no posted results in the dated review, and the identified publication reported baseline characteristics.
Results from the completed pharmacokinetic interaction studies.
Comparative benefit and harm versus another medicine in a direct outcome-focused head-to-head trial.
The identity and quality of any nonstudy product.

Product identity and quality limits

FDA's Survodutide UNII identifies a substance but does not approve or authenticate a product. Sponsor trial evidence applies to defined investigational products. A Survodutide or BI 456906 label on another material does not establish sequence, concentration, purity, sterility, stability, storage, handling, or delivery characteristics.

What has been studied together

A completed 34-person pharmacokinetic study was designed to assess exposure to bupropion, caffeine, and midazolam during Survodutide treatment, and a completed 32-person study was designed to assess ethinylestradiol and levonorgestrel exposure. Neither registry had posted results in the dated review. Registration establishes that coadministration was studied, not what the interaction result was.

The identified Survodutide–semaglutide study uses comparator arms, not coadministration. No broad compatibility conclusion with another GLP-1-active medicine, peptide, or drug is supported. Missing evidence does not establish safety.

What people are hearing

“Published phase 3 results mean Survodutide is FDA approved.” The reviewed original papers describe it as investigational or under investigation.
“Separate Survodutide, retatrutide, semaglutide, and tirzepatide trials prove which is best.” Different populations, protocols, estimands, comparators, and follow-up periods cannot be treated as one head-to-head trial.
“A product sold as Survodutide is the sponsor's phase 3 product.” A name does not establish sequence, concentration, purity, sterility, stability, handling, or delivery characteristics.

Questions readers raise

Readers ask whether phase 3 means approved, whether cross-trial percentages reveal a winner, and whether a product sharing the name is the sponsor's study product. These are questions to investigate, not evidence of approval, superiority, compatibility, or product identity. PepCurrent has not published anecdotal theme counts or public user reviews for this profile.

What would change this answer

An exact FDA approval action and prescribing information.
Published SYNCHRONIZE-2 outcome results.
Posted or published results from the completed pharmacokinetic studies.
A direct outcome-focused head-to-head randomized trial.
Product-level analytical and manufacturing evidence for any separately marketed material.

Sources and records

WADA — 2026 Prohibited List

Educational journalism only; not medical advice. We do not evaluate individual products, recommend use, name vendors, or provide protocols.

Boundary: PepCurrent explains public evidence and regulatory records. We do not evaluate individual products, recommend use, name vendors, or provide protocols.